Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 17 April 2026.

Key details • Transaction size: 23,000 H shares, representing 0.017 % of the company’s 135.99 million issued shares (excluding treasury shares) prior to the transaction.

• Price range: HKD 28.80–30.80 per share, yielding a volume-weighted average cost of HKD 29.7647 per share.

• Aggregate consideration: HKD 0.68 million.

Post-transaction share capital • Issued shares outstanding (excluding treasury shares): 135.97 million. • Treasury shares on hand: 243,900 (increased from 220,900). • Total issued shares (including treasury stock): 136.22 million (unchanged, as repurchased shares are held in treasury).

Repurchase authority status • Current mandate: Up to 13.62 million shares authorised for repurchase by shareholder resolution dated 12 February 2026. • Cumulative repurchases under mandate: 243,900 shares, equivalent to 0.18 % of the issued share base on the mandate date. • Moratorium: Under HKEX rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 17 May 2026 (30 days after the latest repurchase).

All repurchases were conducted in accordance with Hong Kong Listing Rules and the company’s approved buyback mandate.